Cumberland Pharmaceuticals (NASDAQ:CPIX) Releases Quarterly Earnings Results, Hits Expectations

Cumberland Pharmaceuticals (NASDAQ:CPIX) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13), FiscalAI reports. Cumberland Pharmaceuticals had a negative net margin of 6.37% and a positive return on equity of 5.04%. The firm had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million.

Here are the key takeaways from Cumberland Pharmaceuticals’ conference call:

• Cumberland signed a transformational deal with Apotex to sell its U.S. branded commercial portfolio for $100 million cash plus $9 million for inventory, transition fees and a milestone, which management says will materially strengthen the balance sheet and fund a shift to a development-focused strategy.
• First‑quarter revenue from marketed brands was $9.1 million (up ~5% excluding a prior one‑time milestone), with a GAAP net loss of ~$3.3 million and an adjusted loss of $1.9 million ($0.13/share); operating cash flow was positive $387,000 and cash on hand was $11 million.
• The clinical pipeline, led by ifetroban, shows progress—~1,400 subjects dosed, FDA Fast Track plus Orphan/Rare Pediatric designations for Duchenne muscular dystrophy, completed enrollment in scleroderma, and ongoing IPF trials with an interim safety review clearing continuation and interim efficacy expected later this year.
• Commercial and manufacturing wins include FDA expanded labeling for Caldolor (post‑operative pain), FDA clearance of the manufacturing site enabling a planned Vaprisol relaunch this year, launch of Talicia sales promotion, and the first shipment of Vibativ to China—moves management says will broaden patient access prior to the portfolio sale.

Cumberland Pharmaceuticals Stock Up 0.4%

NASDAQ:CPIX traded up $0.02 during trading hours on Tuesday, reaching $4.55. The company’s stock had a trading volume of 318,892 shares, compared to its average volume of 2,829,014. The company has a market capitalization of $68.07 million, a P/E ratio of 50.33 and a beta of -0.06. Cumberland Pharmaceuticals has a 12 month low of $1.85 and a 12 month high of $6.26. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.84 and a current ratio of 1.01. The stock has a 50 day moving average price of $3.45 and a two-hundred day moving average price of $3.42.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of large investors have recently bought and sold shares of CPIX. Perceptive Advisors LLC purchased a new position in Cumberland Pharmaceuticals in the fourth quarter worth $1,358,000. Marshall Wace LLP purchased a new position in Cumberland Pharmaceuticals in the fourth quarter worth $192,000. Geode Capital Management LLC grew its holdings in Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 5,653 shares during the last quarter. Two Sigma Investments LP grew its holdings in Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after purchasing an additional 5,326 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after purchasing an additional 27,980 shares during the last quarter. Institutional investors own 15.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on CPIX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen raised shares of Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cumberland Pharmaceuticals has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.